Too hard to handle? The challenges of handling and delivering highly potent oncology drugs
This Pharma IQ report outlines how to ensure the safe manufacturing, packaging and distribution of oncology drugs that contain highly potent actives
Add bookmark
Cancer therapies have significantly evolved since the first forms of chemotherapy were introduced in the early 20th century, becoming increasingly targeted at malignant tumors without damaging the surrounding healthy tissue.
This requires lower dosage loads, with an increase in potency of the active pharmaceutical ingredient (API). Developing and manufacturing drugs containing potent and highly potent APIs require specialist expertise and technologies to minimize risk to operators and the environment.
This Pharma IQ report, produced in association with PCI Pharma Services, outlines the challenges of handling drugs containing HPAPIs. This exclusive report explores how contract development and how manufacturing organizations (CDMOs) can facilitate the process from beginning to end.
Download this report to find out:
- Which equipment and best practices must be put in place by manufacturing facilities handling highly potent drugs
- The requirements for packaging and distribution to ensure drugs remain effective and safe for patients
- How outsourcing can lead to cost and time efficiencies
